The Anaphase-Promoting Complex/Cyclosome (APC/C) is a large E3 ubiquitin ligase critical for cell cycle regulation, primarily targeting specific proteins for proteasomal degradation to ensure proper progression through mitosis and meiosis. ANAPC2 (also known as APC2) is an essential core subunit of the APC/C, serving as a scaffold for the complex’s assembly and activity. It interacts with other APC/C components, such as ANAPC11 and CDC20/CDH1 coactivators, to mediate substrate recognition and ubiquitination.
ANAPC2 antibodies are widely used tools in cell biology research to study APC/C structure, function, and regulation. They help detect ANAPC2 expression levels, monitor its localization during cell cycle phases, and investigate its role in checkpoint control, chromosome segregation, and cyclin degradation. Dysregulation of APC/C activity, including ANAPC2 mutations or altered expression, has been linked to cancers, genomic instability, and developmental disorders.
These antibodies are commonly validated for techniques like Western blotting, immunoprecipitation, and immunofluorescence. Species specificity (e.g., human, mouse) and cross-reactivity should be confirmed for experimental models. Commercial ANAPC2 antibodies are often raised against conserved regions of the protein, such as the N-terminal cullin homology domain, which is vital for APC/C assembly. Researchers rely on these reagents to explore cell cycle mechanisms, therapeutic targets, and disease pathways associated with APC/C dysfunction.